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Background: Duchenne muscular dystrophy (DMD), an X-linked disorder affects approximately 1 in 5000 males, is
universally associated with heart disease. We previously identified myocardial disease by late gadolinium enhancement
(LGE) in DMD subjects at various stages of disease, but the true prevalence is unclear. Cardiovascular magnetic resonance
(CMR) is well established for both assessment of ventricular function and myocardial fibrosis by LGE. We sought to
establish i) prevalence and distribution of LGE in a large DMD population and ii) relationship among LGE, age, LVEF
by CMR and current living status.
Methods: Current living status, demographic and CMR data including ventricular volumes, LVEF and LGE from 314
DMD patients undergoing evaluation at a single large tertiary referral center were analyzed.
Results: 113 of 314 (36%) of DMD subjects showed LGE positivity with prevalence increasing from 17% of
patients <10 years to 34% of those aged 10–15 years and 59% of those >15 years-old. Patients with LVEF ≥55% were
LGE positive in 30% of cases; this increased to 84% for LVEF <55%. LGE was more prevalent in the free wall (531/1243,
42.7%) vs. septal segments (30/565, 5.3%). Patients with septal involvement were significantly older and had lower LVEF
than those with isolated free wall LGE. Ten percent (11/113) patients who had LGE died 10.8 months after CMR. Only
one patient from the LGE negative group died. Patients who died had higher heart rate, larger left ventricular volume
and mass, greater number of positive LGE segment and increase incident of septal LGE compared to those who
remained alive.
Conclusion: In DMD patients, LGE occurs early, is progressive and increases with both age and decreasing LVEF.
Segmentally, the incidence of the number of positive LGE segments increase with age and lower LVEF. Older patients
and those who died during the study period had more septal LGE involvement. The current studies suggest that the
time course and distribution of LGE-positivity may be an important clinical biomarker to aid in the management of
DMD-associated cardiac disease.
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Figure 1 Examples of LGE by CMR. (Top Panel) 12 year old DMD
patient with no LGE (dark myocardium), (Middle Panel) 8.5 year old
DMD patient with LGE in the free wall only (bright areas shown by
yellow arrows) and (Bottom Panel) 18 year old DMD patient LGE
involving multiple segments including the septum (bright areas
shown by red arrows).
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Duchenne muscular dystrophy (DMD), an X-linked re-
cessive disorder affecting approximately 1 in 5000 males
is the most common inherited muscular dystrophy [1-3].
The disease results from mutations in the gene for dys-
trophin, a sarcolemmal protein, that is abundant in both
cardiac and skeletal muscle [4]. Typically, progressive
skeletal muscle weakness results in loss of ambulation
between 7 and 13 years of age [5,6]. Corticosteroids and
supportive respiratory devices [7-11] have improved
motor and respiratory outcomes, resulting in DMD-
associated cardiac disease as the leading cause of death
typically in the second to third decade of life [8,12,13].
DMD-associated cardiac disease is progressive and ul-
timately results in global ventricular systolic dysfunction,
often with minimal ventricular dilation [14]. End-stage
cardiac pathology includes cardiomyocyte hypertrophy,
atrophy and fibrosis [15-17].
Fibrosis of the left ventricle in DMD has been ob-
served at autopsy [15,17] and during cardiovascular
magnetic resonance (CMR) with late gadolinium en-
hancement (LGE) [18,19]. LGE appears to be associated
with late stages of the disease [19] but the true preva-
lence of LGE and its relationship to disease state, e.g.
age at CMR and left ventricular ejection fraction (LVEF),
is uncertain. The purpose of the current study was to es-
tablish the prevalence of LGE across a large DMD popu-
lation with broad age range and to correlate LGE with
severity of DMD associated cardiac disease as character-
ized by LVEF and living status.
Methods
Study population
Current living status as of December 2012 and demo-
graphic data were analyzed from records of DMD pa-
tients who underwent clinical CMR studies including
LGE between September 2005 and September 2012 at a
single large tertiary referral center. Only patients with
a known diagnosis of DMD confirmed by a skeletal
muscle biopsy showing absent dystrophin and/or DNA
analysis demonstrating a characteristic dystrophin muta-
tion in all patients. The Institutional Review Board at
Cincinnati Children’s Hospital approved the study.
Cardiac magnetic resonance imaging protocols and
data analysis
CMR was conducted either on a Siemens 3 Tesla Trio
(Siemens Medical Solutions, Malvern, PA/Erlangen,
Germany), Philips 3 Tesla Achieva (Philips Healthcare,
Andover, MA) or on a 1.5 Tesla GE Signa Excite
(General Electric Healthcare; Milwaukee, WI). Machine
type was based solely on clinical availability, independ-
ent of the patient’s clinical status. Cardiac functional
imaging was performed using a standard retrospectiveECG-gated, segmented steady state free precession (SSFP)
technique and includes a short axis stack of cine SSFP im-
ages from cardiac base to apex as previously described
[20,21]. Typical scan parameters included FOV = 32–38
cm, slice thickness = 5–6 mm, NEX = 2 (breath hold; 4–5
for free breathing), TE/TR = 1.4/2.8 (Siemens), TE/TR =
2.0/4.0 (GE), in-plane resolution = 1.2– 2.2 mm. A mini-
mum of 12 slices were performed. The typical temporal
resolution of the cine SSFP images was 30–40 ms and was
adjusted according to the patient’s heart rate and ability to
breath-hold. The RF flip angles were set between 50°–70°
dependent on the patient weight, height and the SAR level.
Left ventricular volumes, mass and LVEF were assessed via
standard planimetry techniques using semi-automated
computer software (QMASS v.6.1.5, Medis Medical Im-
aging Systems, Netherlands) [20,21]. LGE status, ventricular
volumes, mass, and EF along with subject demographic
data were tabulated for each subject, and then exported to
a spreadsheet file for off-line analysis.
LGE imaging was performed via a FLASH inversion
sequence recovery protocol 5–8 minutes after 0.2 mmol/kg)
gadolinium-based contrast agent injection as previously
described [22,23]. The LGE sequence was independ-
ently analyzed by a single expert reader (KNH) blinded
to the clinical report. LGE was deemed negative or
positive globally at the base, mid-ventricle and apex as
well as in each of 16 myocardial segments by visual rat-
ing [24] (Figure 1). At our center it is a standard of
practice to report the presence of LGE using the modi-
fied 16-segment model which is exactly the same
method we used for this study. The primary reader
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presence of LGE without knowing the LGE status of
the clinical report. For intra- and interobserver variabil-
ity, the clinical LGE description from a subset of 60
randomly selected CMR studies from each of the pri-
mary reader (KNH) and a second CMR cardiologist
(MDT) (30 LGE negative and 30 LGE positive studies)
were reviewed.
Statistical methods
Study results are expressed as mean ± SD for continuous
data and as percentages and numbers for categorical
data. Continuous variables were compared using two-
sample t-test and categorical variables were compared
using Fisher exact-test. LGE data were classified as being
positive or negative and analyzed using a logistic regres-
sion model to estimate the odds ratio (OR) and 95%
confidence interval (CI) between the patient aged: 10–
15 years and > 15 years as compared to the reference age
group of < 10 years. Similar model was used to estimate
the OR (95% CI) between the LVEF of subjects with
LVEF < 55% compared to those with LVEF ≥ 55%. Seg-
ments were summarized across the above age and LVEF
groups. All tests were 2-sided, and a p-value < 0.05 was
considered statistically significant. SAS version 9.2 (SAS
Institute Inc., Cary, NC) was used for all analyses.
Results
Patient stratification
A total of 330 males, ages 6 to 28 years, with DMD
underwent clinical CMR evaluation during the study
period (Table 1). 16 subjects were excluded due a lack of
intravenous access. Patients were dichotomized as LGE
negative and LGE positive if any LV myocardial segment
showed LGE positivity; 113/314 (36%) subjects were
deemed LGE positive. LGE was always distributed in the
sub-epicardial region and spares the sub-endocardium re-
gion. LGE-negative patients were younger than LGE posi-
tive patients (11.8 ± 3.4 vs. 15.2±5.1 years, p < 0.0001).Table 1 Demographic and CMR findings between LGE negativ
Patient groups LGE negative (n = 201)
Age (years) 11.8 ± 3.4 (6–28)
Heart rate (bpm) 100.8 ± 14.1 (55–143)
BSA (m2) 1.2 ± 0.33 (0.8-2.6)
Height (cm) 135.5 ± 16.9 (108–191)
Weight (kg) 42 ± 19.2 (19–136)
LVEF (%) 64.8 ± 5.4 (35–78)
LVEDV/BSA (mL/m2) 67.9 ± 13.9 (31–107)
LVM/BSA (g/m2) 46.3 ± 9.9 (24–78)
Abbreviations: BPM Beat Per Minute, BSA Body Surface Area, CM Centimeter, CMR Ca
g gram, kg Kilogram, LGE Late Gadolinium Enhancement, LVEF Left Ventricular Eject
Mass, mL Milliliter, m2 Meter Square, n Number of patients.Heart rate did not differ between the two groups but
height; weight and BSA were higher in the LGE positive
patients as expected based on older age. LVEF was
lower and indexed left ventricular end-diastolic volume
(LVEDV/BSA) and mass (LVM/BSA) were significantly
larger for LGE positive compared to LGE negative patients
suggesting more advanced heart disease (Table 1). Of the
patients that were LGE positive, 11/113 (10%) died during
the study period. Patients who died during the study
period were older (19.5 ± 5.9 vs 14.7 ± 4.8 years, p =
0.003), had higher heart rates (110 ± 21 vs 96 ± 13.9 bpm,
p = 0.003), larger ventricular volume (128.2 ±46.2 vs
73.1 ± 16.9 mL/m2, p < 0.0001), ventricular mass (69 ±
11.8 vs 51 ± 12.5 g/m2, p < 0.0001), lower LVEF (32 ±13.9
vs 59.7 ± 7.5 percent, p < 0.0001) and greater number of
positive LGE segments (9.6 ± 4.2 vs 4.5 ± 2.4, p < 0.0001)
compared to those who remained alive (Table 2).
When compared to the clinical reports of the 60 ran-
domly selected CMR reports from the primary reader
( KNH) and 60 clinical reports from a second cardiolo-
gist (MDT), there was 100% agreement with the pri-
mary reader’s (KNH) clinical LGE findings and the
LGE findings later performed for the study. Likewise,
there was 100% agreement between the clinical LGE
findings of the second cardiologist (MDT) and the
LGE findings later performed by the primary reader
(KNH).
Patients were stratified into groups based on age
(<10 years old, 10–15 years old and >15 years) and nor-
mal LVEF (≥ 55%) or reduced LVEF (< 55%) (Table 3).
Among patients <10 years old 17% were LGE positive,
this increased to 34% for those 10–15 year old and to
59% for those > 15 year old. Age was very strongly asso-
ciated with presence of LGE with an odds ratio of 2.6
(age 10–15 years) and 7 (age > 15 years). In patients with
LVEF ≥55% LGE positivity was seen in 30% but with
LVEF < 55% this number increased to 84%. LVEF was a
powerful predictor of presence of LGE with an odds ra-
tio of 12.3 for those with LVEF < 55% (Table 3).e and LGE positive patient groups
LGE positive (n = 113) P-value
15.2 ± 5.1 (7–32) <0.0001
98 ± 15.7 (48–149) 0.056
1.4 ± 0.3 (0.9-2.4) <0.0001
147.3 ± 16.8 (117–191) 0.0004
52 ± 18.1 (24–106) <0.0001
57 ± 11.6 (17–79) <0.0001
76.9 ± 26.4 (35–207) 0.0004
51.7 ± 13.2 (29–109) <0.0001
rdiac Magnetic Resonance Imaging, DMD Duchenne Muscular Dystrophy,
ion Fraction, LVEDV Left Ventricular End-Diastolic Volume, LVM Left Ventricular
Table 2 CMR findings and living status in DMD patients
Patient groups Alive (n = 102) Not alive (n = 11) P-value
Age (years) 14.7 ± 4.8* 19.5 ± 5.9 0.003
Heart rate (bmp) 96 ± 13.9* 110 ± 21 0.003
CMR to death (months) N/A 10.8 ± 8.5 N/A
LVEF (%) 59.7 ± 7.5* 32 ±13.9 <0.0001
LVEDV/BSA (mL/m2) 73.1 ± 16.9* 128.2 ±46.2 <0.0001
LVM/BSA (g/m2) 51 ± 12.5* 69 ± 11.8 < 0.0001
NPS with LGE 4.5 ± 2.4* 9.6 ± 4.2 <0.0001
Segments with LGE (%) 455/1632 (28%) 106/176 (60%) N/A
Septal LGE (%) 13/510 (2.5%) 17/55 (31%) N/A
Abbreviations: BMP Beats per minute, CMR Cardiac Magnetic Resonance
Imaging, DMD Duchenne Muscular Dystrophy, LGE Late Gadolinium
Enhancement, LVEF Left Ventricular Ejection Fraction, LVEDV/BSA Left
Ventricular End-Diastolic Volume Indexed to Body Surface Area, LVM/BSA Left
Ventricular Mass Indexed to Body Surface Area, g/m2 Grams Per Meter Square,
mL Milliliter, NPS Number of Positive Segments, *Indicates
Statistical Significance.
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cent) as the main clinical outcome using a logistic model
was performed. An un-adjusted model with +/−LGE in
the model as a covariate which resulted in estimated OR
for +/−LGE of 12.3 (95% CI 4.9, 30.6; p < 0.0001 and c-
statistic = 77%) in predicting reduced EF was performed.
Then age (as continuous variable) was added into the
model resulted in an adjusted OR for +/−LGE of 7.6
(95% CI 2.9, 19.7; p < 0.0001 and c-statistic = 85%) in
predicting reduced EF. Similar analysis using +/−septal
LGE as a covariate in the model and LVEF as the main
clinical outcome was conducted and this resulted in un-
adjusted estimated OR for +/−septal LGE of 7.0 (95% CI
2.3, 21.1; p = 0.0006 and c-statistic = 64%) in predicting
reduced EF. Then age (as continuous variable) was
added into the model with resulted in an adjusted OR
for +/−septal LGE of 5.2 (95% CI 1.6, 16.5; p = 0.0059
and c-statistic = 78%) in predicting reduced EF.
LGE has a regional distribution
Figure 2 shows a plot of age and LVEF for each patient
(LGE-negative shown in blue and LGE-positive shown in
red). To quantify a segmental analysis of LGE, we ana-
lyzed studies of 113 patients that were LGE positive. TheTable 3 CMR Findings between LGE negative and LGE positiv
Parameters # Patients LGE negative LGE positiv
Age < 10 years 83 69 (83%) 14 (17%)
Age 10–15 years 149 98 (66%) 52 (34%)
Age > 15 years 82 34 (41%) 48 (59%)
LVEF ≥ 55% 277 195 (70%) 82 (30%)
LVEF < 55% 37 6 (16%) 31 (84%)
Abbreviations: # Number, CI Confidence Interval, CMR Cardiac Magnetic Resonance I
Enhancement, LVEF Left Ventricular Ejection Fraction, NPS Number of Positive Segmnumber of LGE positive segments was associated older
age and lower LVEF (Figure 3A-B). Of the 1808 segments
analyzed, 565 were septal segments and 1243 were free
wall segments. For each CMR study, the number of LGE
positive segments ranged from 1 to 13 (Figure 3A-B). In
subjects < 10 years of age, mean number of LGE positive
segments was 4.4±3.0. This increased to 4.8±2.5 for sub-
jects 10–15 years of age and 5.9±3.3 LGE positive
segments for subjects >15 years old. For subjects with
LVEF ≥ 55%, mean number of LGE positive segments
was 4.1±2.4 versus 7.8±3.4 LGE positive segment for
LVEF > 55% (Table 3). Overall, LGE was more prevalent
in the free wall segments compared to the septal seg-
ments 42.7% (531/1243) versus 5.3% (30/565). At the
base and mid-ventricle LGE was most prevalent in an-
terolateral (n = 190), inferolateral (n = 165) and inferior
segments (n = 54) and less common in the anterior seg-
ment (n = 26). Of the septal segments, the anteroseptal
segment (n = 17) was more commonly affected than the
inferoseptal segment (n = 5). At the apical level, the
findings are similar with the lateral segments (n = 58)
most commonly affected compared to the inferior (n = 19)
and anterior (n = 19) segments and apical septal segment
least affected (n = 8) (Figure 4).
Predictors of Septal vs. Isolated Free Wall LGE
Septal LGE-positivity was never found in isolation and
only in association with LGE positivity in other free
wall segments. Patients with septal LGE involvement
were older than those without septal LGE involvement
(18.3 ± 5.5 vs 14.6 ± 4.9, p =0.006), though heart rate and
BSA were not statistically different between the two
groups. Among patients age < 10 years (n = 14) the inci-
dence of septal LGE was 7.1% (95% CI, 0.18 – 33.8), for
those age 10–15 years (n = 51) the incidence of septal
LGE of 7.8% (95% CI, 2.2-18.9) and increased to 25%
(95% CI, 13.6 – 39.6) for patients > 15 years of age
(n = 48) (Table 4). The number of total positive LGE
segments was greater when LGE was evident in the
septum (4.2 ± 2.2 versus 9.4 ± 3.1, p < 0.0001). Further-
more, septal LGE was associated with greater indexed
left ventricular end-diastolic volume (111.2 ± 44.1 ver-
sus 72.7 ± 17.1, p < 0.0001) and left ventricular masse DMD patient compared to age and LVEF
e NPS with LGE Odds ratio (95% CI) P value
4.4 ± 3.0 1.0 —————
4.8 ± 2.5 2.6 (1.3-5.0) < 0.006
5.9 ± 3.3 7.0 (3.4-14.3) < 0.0001
4.1 ± 2.4 1.0 —————
7.8 ± 3.4 12.3 (4.9-30.6) < 0.0001
maging, DMD Duchenne Muscular Dystrophy, LGE Late Gadolinium
ents.
Figure 2 Scatter graph of LVEF versus age. The LVEF of LGE negative (blue diamonds) and LGE positive (red square) patients are plotted
against age demonstrating LGE was associated with older age and lower LVEF.
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lower LVEF (42.6 ± 16.9 versus 59.5 ± 8.3, p < 0.0001) at
the time of CMR (Table 4). Patients who died during
the study period not only have greater number of LGE
positive segments, the percent of segments with LGE
was higher with 106/176 (60%) vs455/1632 (28%) and
had more septal involvement 17/55 (31%) vs 13/510
(2.5%) compared to those who remained alive during
the study period (Table 2).Figure 3 Scatter plot of number of LGE positive segment versus age
compared to age (A) and LVEF (B). The number of LGE positive segmentsDiscussion
This is the first study to establish prevalence and distri-
bution of LGE in a large DMD population and to estab-
lish the relationship to age and LVEF. The major finding
of this study is that in DMD patients, LGE-positivity, an
established indicator of injured or fibrotic myocardium,
is more prevalent with increasing age and decreasing
LVEF. This is not unexpected as observations in other
forms of heart disease, e.g. ischemic, hypertrophic andand LVEF. Scatter Plot of the Number of LGE positive segment
was associated older age and lower LVEF.
Figure 4 Global and segmental LGE. (A) LGE was more prevalent in the free wall segments (red) compared to the septal segments (gray)
42.7% (531/1243) versus 5.3% (30/565). (B) Segmentally, free wall segments (red) were more commonly affected with LGE than the septal
segments (gray).
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suggest that LGE-positivity is associated with worse out-
comes, likely representing common end stage process
regardless of underlying disease pathogenesis [25-33]. In
addition, the cohort of patients that died during the
study period not only have greater number of positive
LGE segments but greater percent of septal LGE in-
volvement associated with increase heart rate, left ven-
tricular volume, mass and ejection fraction. Further,
findings in the patients we studied suggest that the dis-
tribution of LGE, i.e. free wall only vs free wall plus sep-
tal may be indicative of heart disease severity.
The presence of LGE was initially reported in 8 boys
with DMD by Silva et al. [18]. Subsequently, PuchalskiTable 4 CMR findings between patients with no septal LGE an
Patient groups No septal involvement (n = 96)
Age (years) 14.6 ± 4.9*
Heart rate (bmp) 97.5 ± 16.7
BSA (m2) 1.4 ± 0.32
LVEF (%) 59.5 ± 8.3*
LVEDV/BSA (mL/m2) 72.7 ± 17.1*
LVM/BSA 51.3 ± 12.7*
NPS with LGE 4.2 ± 2.2*
Age < 10 years (n = 14) ————————————
Age 10 – 15 years (n = 51) ————————————
Age > 15 years ( n = 48) ————————————
Abbreviations: BSA Body Surface Area, BMP Beats per minute, CI Confidence Interval
LVEF Left Ventricular Ejection Fraction, LVEDV Left Ventricular End-Diastolic Volume,
NPS Number of Positive Segments, * = P value (<0.05) is significant.et al. reported 74 patients with DMD, 32% had LGE in-
volving the posterobasal region of the LV in a subepicar-
dial distribution [19]; they reported that more advanced
DMD-associated heart disease correlated to the presence
of LGE in the inferior and left lateral free wall with
transmural fibrous replacement. Results of the current
study confirm that boys with LGE-positivity were signifi-
cantly older and had lower LVEF than those without
LGE. However, we report for the first time an associ-
ation of global and segmental LGE with age and EF. The
youngest DMD patient in our cohort to have LGE was
7.6 years age despite normal LVEF which indicates that
DMD-associated heart disease in the form of LGE can
occur before age 10 years of age. Walcher et al. analyzedd those with septal LGE involvement
Septal involvement (n = 17) P-value
18.3 ± 5.5 0.006
97.3 ± 7.9 0.97
1.5 ± 0.29 0.22
42.6 ±16.9 <0.0001
111.2 ±44.1 <0.0001
61.1 ± 15.2 0.006
9.4 ± 3.1 <0.0001
7.1% (95% CI, 0.18-33.9) 0.001
7.8% (95% CI, 2.2-18.9) <0.0001
25.0% (95% CI, 13.6-39.6) 0.0005
, CMR Cardiovascular Magnetic Resonance, LGE Late Gadolinium Enhancement,
LVM Left Ventricular Mass, mL Milliliter, m2 Meter Square, n Number of patients,
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(7 patients in total) and concluded that LGE is present
prior to the onset of global left ventricular dysfunction
[34]. Bilchick et al. evaluated the prevalence and distri-
bution of regional scar on dysfunctional myocardial seg-
ments in a small DMD patient population (16 patients)
and concluded that overall scar prevalence in inferior,
inferolateral and anterolateral segments was eight times
higher than in inferoseptal, anteroseptal and anterior
segments [35,36]. Our study demonstrated a similar dis-
tribution of LGE but in a considerably larger cohort,
notably the largest, of DMD CMR exams.
The finding of LGE, a measure of cardiac fibrosis and
progressive cardiac disease in DMD boys, is intuitively
expected but the natural history has been poorly charac-
terized with regards to the age of onset and association
with LV systolic dysfunction. DMD results from muta-
tion in the gene for the protein dystrophin. Dystrophin
provides a structural link between the cytoskeleton and
the extracellular matrix, and mutations result in greatly
reduced or absent dystrophin resulting in a loss of
cell membrane integrity. A long-standing hypothesis
regarding DMD disease pathogenesis implicates loss of
membrane integrity as a primary event leading to degen-
eration of myocytes. Intermittent tears in the cell mem-
brane permit influx of calcium that leads to a destructive
cascade culminating in myocyte necrosis, inflammation,
and fibrosis [37-39]. These processes are ongoing in
early stages of disease, but a cumulative effect is required
for clinical detection by LGE using CMR.
While the mechanism of myocardial injury in DMD
remains somewhat speculative, Mavrogeni et al. reported
on a population of 20 patients with DMD and found
that6 patients were LGE positive; LGE positive patient, 4
had CMR (STIR-T2 weighted imaging) evidence of myo-
carditis. All 6 patients with LGE had histologic evidence
of myocarditis and rapid deterioration of LVEF was
noted in those patients in 1 year follow up CMR [40,41].
Wansapura et al. demonstrated increase in the hetero-
geneity of T2 signal with increasing age and decreasing
LVEF, likely representing micro fibrosis (shortening T2)
coexisting with tissue edema (prolonging T2) [42]. In a
novel therapeutic approach to DMD in a murine DMD
model, Rafael-Fortney et al. showed marked reduction
in myocardial fibrosis with the use of lisinopril and
spironolactone [43]. The ability to quantify myocardial fi-
brosis noninvasively in humans using LGE-CMR suggests
it may be a useful biomarker endpoint for therapeutic
clinical trials.
Study limitations
This was a retrospective study and as a result is subject
to accepted limitations of this design. There is no correl-
ation with LGE findings with medications such time onsteroid and ACE inhibition, however patients are typic-
ally on steroid by age 5 years and typically remain on
the steroid regimen for life. ACE inhibition is typically
added by age 10 years or when there are signs of left
ventricular dysfunction is evident by echocardiogram
and independent of LGE findings. Although we have
mortality data the numbers were small and since all pa-
tients died out of the hospital, we do not have the cause
of death. The purpose was to define the natural history
of LGE presence in the DMD population; future studies
should focus on correlations with clinical outcomes
(such as hospitalization and heart failure classification)
and genotype-phenotype correlations. It is acknowledged
that this would be valuable information and warrants
additional future investigation. In addition, the data was
accrued from a single center which could be seen as a
limitation or a strength as it facilitated consistent image
acquisition and interpretation. Only qualitative assess-
ment of LGE is available for this study. We found it dif-
ficult to perform quantitative assessment of LGE in our
patient population using either threshold or full width at
half maximum (FWHM) methods, nature of the disease
and epicardial LGE location bordering on epicardial fat
compared to those reported in ischemic heart disease.
T1 mapping, an emerging technique for characterization
of the myocardial extracellular space, was not used in
this work and warrants ongoing evaluation in DMD car-
diomyopathy [44].Conclusions
This study documents evidence of scar burden at an age
earlier than has been previously described for DMD-
associated cardiac disease [45]. As such, these findings
alter our understanding of DMD cardiac manifestations
as it was previously felt that the myocardium was rarely
affected by fibrosis prior to the age of 10 years [10,11].
Evaluation of the myocardium by CMR to document the
presence of LGE may have important implications for
the ongoing management of boys with DMD. We specu-
late that in future studies, LGE may prove to be a useful
biomarker and could serve as the outcome of thera-
peutic strategies to assess utility of antifibrotic agents
such as spironolactone or eplerenone to alter the natural
history of DMD-associated cardiac disease [43,46,47].Abbreviations
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